ORY-1001 is a potent and selective LSD1 inhibitor that induces H3K4me2 accumulation on LSD1 target genes, differentiation of leukemic cells, and inhibition of leukemic stem cell activity in AML models [80]. This evidence concerns the gene KDM1A and acute myeloid leukemia.